We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
51
Ardelyx
ARDX
$997M
$2.41M 0.45%
490,743
+459,708
+1,481% +$2.47M
DVAX
52
DELISTED
Dynavax Technologies
DVAX
$2.2M 0.41%
+170,000
New +$2.25M
ARVN icon
53
Arvinas
ARVN
$572M
$2.2M 0.41%
+313,354
New +$4.91M
ASPC
54
A SPAC III Acquisition Corp
ASPC
$24.8M
$2.16M 0.4%
+215,000
New +$2.15M
RYTM icon
55
Rhythm Pharmaceuticals
RYTM
$7.96B
$1.95M 0.36%
36,890
+5,949
+19% +$330K
SMMT icon
56
CALL
Summit Therapeutics
SMMT
$11.1B
$1.93M 0.36%
+100,000
New +$2.01M
DCTH icon
57
Delcath Systems
DCTH
$524M
$1.9M 0.35%
149,385
– –
CRNX icon
58
Crinetics Pharmaceuticals
CRNX
$8.92B
$1.78M 0.33%
53,125
– –
KALA icon
59
KALA BIO
KALA
$14.5M
$1.71M 0.32%
5,979
+1,572
+36% +$595K
VIR icon
60
Vir Biotechnology
VIR
$1.49B
$1.62M 0.3%
250,000
+185,933
+290% +$1.65M
RCKT icon
61
Rocket Pharmaceuticals
RCKT
$394M
$1.61M 0.3%
241,800
+30,400
+14% +$300K
TSHA icon
62
Taysha Gene Therapies
TSHA
$1.89B
$1.48M 0.28%
1,066,309
+888,602
+500% +$1.49M
VKTX icon
63
Viking Therapeutics
VKTX
$4B
$1.43M 0.27%
59,413
+50,113
+539% +$1.58M
FULC icon
64
Fulcrum Therapeutics
FULC
$297M
$1.41M 0.26%
490,532
+294,284
+150% +$1.08M
CRGX
65
DELISTED
CARGO Therapeutics
CRGX
$1.39M 0.26%
+341,515
New +$2.29M
ORKA
66
Oruka Therapeutics
ORKA
$5.96B
$1.36M 0.25%
+132,780
New +$1.66M
SLNO
67
DELISTED
Soleno Therapeutics
SLNO
$1.35M 0.25%
18,830
-18,000
-49% -$876K
VRNA
68
DELISTED
Verona Pharma
VRNA
$1.27M 0.24%
20,000
-9,100
-31% -$544K
CKPT
69
DELISTED
Checkpoint Therapeutics
CKPT
$1.24M 0.23%
+305,800
New +$1.02M
ALDX icon
70
Aldeyra Therapeutics
ALDX
$93.5M
$1.22M 0.23%
211,579
-436,381
-67% -$2.58M
KRRO icon
71
Korro Bio
KRRO
$195M
$1.2M 0.22%
68,715
+10,737
+19% +$318K
CTNM
72
Contineum Therapeutics
CTNM
$566M
$1.18M 0.22%
168,765
+86,531
+105% +$787K
TECX
73
Tectonic Therapeutic
TECX
$606M
$1.11M 0.21%
62,603
+3,895
+7% +$127K
VRDN icon
74
Viridian Therapeutics
VRDN
$2.67B
$1.06M 0.2%
79,000
+53,000
+204% +$903K
VTGN icon
75
VistaGen Therapeutics
VTGN
$12.8M
$1.05M 0.2%
420,765
+299,304
+246% +$847K
1 2
3
4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.